Q-omics provides the consensus-scored LRRC2 profile across patient tissues and cancer cell-line models. LRRC2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LRRC2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LRRC2 RNA expression shows 18,968 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where LRRC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC2 survival associations across molecular data types. LRRC2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC2 RNA expression–survival associations across cancer types. High LRRC2 expression shows unfavorable associations in LGG and DLBC, but favorable associations in BRCA, COAD, LIHC and PAAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LRRC2 RNA expression.
This table summarizes LRRC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC2 shows lower tumor expression in KIRC, BLCA, KIRP, THCA, LUAD and UCEC. The KIRC box plot shows higher LRRC2 RNA expression in normal versus tumor tissue (log2 FC = −3.095, t-test p < 0.001).
This table shows molecular features associated with LRRC2 in patient tissues and cancer cell lines. In patient samples, LRRC2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
